Abstract
139P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have